NCT06439784Not yet recruiting
Contribution of the VERITON-CT Camera in Prostate Bone Radiostereotaxy
Contribution of 99mTc-HDP Whole-body SPECT/CT Imaging by VERITON-CT CZT Camera in Stereotactic Radiotherapy Treatment of Bone Metastases of Prostate Cancer
Source: ClinicalTrials.gov · Last updated 24 Jul 2026
Brief summary (registry, in English)
Stereotactic radiotherapy enables bone metastases to be treated with highly precise irradiation beams, enabling small targets to be irradiated. Planning requires the use of cross-sectional imaging such as computed tomography (CT) or magnetic resonance imaging (MRI). Bone scintigraphy with Tc99m-labelled biphosphonates (T1/2=6h) is indicated in the extension assessment of prostate cancers. Thanks to the advent of single-photon emission computed tomography (SPECT) based on CZT detectors; whole-body SPECT is now compatible with clinical constraints. We propose to study the value of using whole-body SPECT for planning stereotactic radiotherapy of metastatic prostate cancer. This is a prospective, single-center, non-randomized study involving 30 patients. Patients will benefit from routine examinations (CT scan, MRI) including a bone SPECT/CT in treatment position performed on the VERITON-CT (Spectrum Dynamics, Haifa, Israel). Planning based on whole-body SPECT images will be carried out remotely from the patient's point of care. The examination will be interpreted by the nuclear physician, and planning will be based on the dosimetric CT scanner, as in standard management. Virtual replanning will be carried out at distance from treatment, incorporating SPECT imaging. Treatment plans with and without SPECT will be compared quantitatively and qualitatively. The feasibility of SPECT imaging in the treatment position will be assessed, enabling lesion location imaging and dosimetric scanning to be performed in a single examination. All therapeutic management and clinical follow-up will be carried out as part of routine care.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 28 May 2024
- Start date
- 15 Sept 2026
- Primary completion date
- 15 Sept 2027
- Lead sponsor
- Centre Henri Becquerel
- Diseases
- Prostate cancer
- NCT number
- NCT06439784
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 15 Sept 2026 to the primary completion date, 15 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Presence of active cancer in the previous three years
Other illness
- Hypersensitivity to HDP or to one of the excipients of the radiopharmaceutical.
- History of radiotherapy of the volume to be treated by stereotaxy.
Other
- Protected adults (under guardianship or curatorship)
- Unable to undergo medical monitoring for geographical, social or psychological reasons
- Unable to decubitus (orthopnea, etc.),
Who the study is looking for
- Age ≥ 18 years,
- Good general health WHO ≤ 1
- Informed and signed consent prior to any specific study procedure.
- Patient affiliated to the social security system
- Bone metastases from prostate cancer
- Indication for bone stereotactic radiotherapy
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre Henri Becquerel Coordinator of this site? Confirm its status | Rouen | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.